Ocugen’s GA gene therapy shows potential edge over rivals in early phase 2 data
TL;DR
Ocugen reports preliminary phase 2 data for OCU410 to treat geographic atrophy (GA) from dry AMD, with the medium dose showing a 54% reduction in lesion growth vs placebo at 12 months and the high dose 36% in a small patient subset, raising questions about dose response; Ocugen aims to present full data this quarter and move to phase 3 by year-end, targeting an FDA filing in 2028, and argues the therapy could outperform Apellis' Syfovre and Astellas' Izervay.
- Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas Fierce Biotech
- Ocugen unwraps mid-stage data for eye disease gene therapy Endpoints News
- A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights Nature
- Ocugen says gene therapy continues to slow damage in GA secondary to dry AMD FirstWord Pharma
- Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial Ophthalmology Times
Want the full story? Read the original reporting
Read on Fierce Biotech